Shrinivas Rathod

Dr. Shrinivas Rathod


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
SRShrinivas Rathod
Shrinivas Rathod
BJBranislav Jeremic
Branislav Jeremic
ADArbind Dubey
Arbind Dubey
MGMeredith Giuliani
Meredith Giuliani
BBBashir Bashir
Bashir Bashir
RKRashmi Koul
Rashmi Koul

1 September 2018 in Lung Cancer
Verified
Journal Article
Closed access
RKRashmi Koul
Rashmi Koul
SRShrinivas Rathod
Shrinivas Rathod
ADArbind Dubey
Arbind Dubey
BBBashir Bashir
Bashir Bashir
ACAmitava Chowdhury
Amitava Chowdhury

7 April 2020 in Radiotherapy and Oncology
Verified
Journal Article
Open access
PDF file
SRShrinivas Rathod
Shrinivas Rathod
ADArbind Dubey
Arbind Dubey
BBBashir Bashir
Bashir Bashir
GSGokulan Sivananthan
Gokulan Sivananthan
ALAhmet Leylek
Ahmet Leylek
RKRashmi Koul
Rashmi Koul
As COVID-19 pandemic continues to explode, cancer centers worldwide are trying to adapt and are struggling with this constantly changing scenario. Intending to ensure patient safety and deliver quality care, we sought consensus on the preferred thoracic radiation regimen in a Canadian province with 4 new R’s of COVID era.

4 January 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
MAMarina AduQuaye
Marina AduQuaye
SDSheen Dube
Sheen Dube
BBBashir Bashir
Bashir Bashir
ACAmitava Chowdhury
Amitava Chowdhury
NANaseer Ahmed
Naseer Ahmed
SRShrinivas Rathod
Shrinivas Rathod
Introduction: We evaluated the association of pre-treatment immunologic biomarkers on the outcomes of early-stage non-small-cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT). Materials and methods: In this retrospective study, all newly diagnosed early-stage NSCLC treated with SBRT between January 2010 and December 2017 were screened and included for further analysis. The pre-treatment neutrophil-lymphocyte ratio (NLR), monocyte lymphocyte ratio (MLR), and platelet-lymphocyte ratio (PLR) were calculated. Overall survival (OS) and recurrence-free survival (RFS) were estimated by Kaplan–Meier. Multivariable models were constructed to determine the impact of different biomarkers and the Akaike information criterion (AIC), index of adequacy, and scaled Brier scores were calculated. Results: A total of 72 patients were identified and 61 were included in final analysis. The median neutrophil count at baseline was 5.4 × 109/L (IQR: 4.17–7.05 × 109/L). Median lymphocyte count was 1.63 × 109/L (IQR: 1.29–2.10 × 109/L), median monocyte count was 0.65 × 109/L (IQR: 0.54–0.83 × 109/L), median platelet count was 260.0 × 109/L (IQR: 211.0–302.0 × 109/L). The median NLR was 3.42 (IQR: 2.38–5.04), median MLR was 0.39 (IQR: 0.31–0.53), and median PLR was 156.4 (IQR: 117.2–197.5). On multivariable regression a higher NLR was associated with worse OS (p = 0.01; HR-1.26; 95% CI 1.04–1.53). The delta AIC between the two multivariable models was 3.4, suggesting a moderate impact of NLR on OS. On multivariable analysis, higher NLR was associated with poor RFS (p = 0.001; NLR^1 HR 0.36; 0.17–0.78; NLR^2 HR-1.16; 95% CI 1.06–1.26) with a nonlinear relationship. The delta AIC between the two multivariable models was 16.2, suggesting a strong impact of NLR on RFS. In our cohort, MLR and PLR were not associated with RFS or OS in multivariable models. Conclusions: Our study suggests NLR, as a biomarker of systemic inflammation, is an independent prognostic factor for OS and RFS. The nonlinear relationship with RFS may indicate a suitable immunological environment is needed for optimal SBRT action and tumoricidal mechanisms. These findings require further validation in independent cohorts.

1 July 2020 in Advances in Radiation Oncology
Verified
Journal Article
Open access
SRShrinivas Rathod
Shrinivas Rathod
ADArbind Dubey
Arbind Dubey
ACAmitava Chowdhury
Amitava Chowdhury
BBBashir Bashir
Bashir Bashir
RKRashmi Koul
Rashmi Koul

15 September 2021 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
PSPawel Siciarz
Pawel Siciarz
SASalem Alfaifi
Salem Alfaifi
EUEric Van Uytven
Eric Van Uytven
SRShrinivas Rathod
Shrinivas Rathod
RKRashmi Koul
Rashmi Koul
BMBoyd McCurdy
Boyd McCurdy
To create and investigate a novel, clinical decision-support system using machine learning (ML). The ML model was developed based on 79 radiotherapy plans of brain tumor patients that were prescribed a total dose of 60 Gy delivered with volumetric-modulated arc therapy (VMAT). Structures considered for analysis included planning target volume (PTV), brainstem, cochleae, and optic chiasm. The model aimed to classify the target variable that included class-0 corresponding to plans for which the PTV treatment planning objective was met and class-1 that was associated with plans for which the PTV objective was not met due to the priority trade-off to meet one or more organs-at-risk constraints. Several models were evaluated using double-nested cross-validation and an area-under-the-curve (AUC) metric, with the highest performing one selected for further investigation. The model predictions were explained with Shapely additive explanation (SHAP) interaction values. The highest-performing model was Logistic Regression achieving an accuracy of 93.8 ± 4.1% and AUC of 0.98 ± 0.02 on the testing data. The SHAP analysis indicated that the ΔD99% metric for PTV had the greatest influence on the model predictions. The least important feature was ΔDMAX for the left and right cochleae. The trained model achieved satisfactory accuracy and can be used by medical physicists in a data-driven quality assurance program as well as by radiation oncologists to support their decision-making process in terms of treatment plan approval and potential plan modifications. Model explanation analysis showed that the model relies on clinically valid logic when making predictions.